Identification and validation of Protein biomarkers of response to neoadjuvant platinum chemotherapy in muscle invasive urothelial carcinoma

Academic Article


  • Background: The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial carcinoma of the bladder (MIBC) treated with cystectomy alone is approximately 50%. Platinum based neoadjuvant chemotherapy (NAC) plus cystectomy results in a marginal 5-10% increase in 5-year CSS in MIBC. Interestingly, responders to NAC (
  • Published In

  • PLoS One  Journal
  • Digital Object Identifier (doi)

    Author List

  • Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque M; Berman D
  • Volume

  • 10
  • Issue

  • 7